Furthermore, our results demonstrate that for patients with varying degrees of PD-L1 positive expression in advanced ESCC, selecting the appropriate first-line immunotherapy regimen can lead to improved survival outcomes. Here, CD274 is linked to esophageal squamous cell carcinoma.